All In MedTech

Device Trial Radar · NCT05920473

Efficacy and Safety Study: Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Movement Disorders in Patients With Intracranial Hemorrhage (ICH).

Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Movement Disorders in Patients With Intracranial Hemorrhage (ICH): A Randomized, Blinded, Sham-controlled Trial.

Last checked: Nov 20, 2026Latest source record: Jun 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

130

Planned (sponsor's estimate)

Start

Jul 1, 2023

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Rehabilitation Hospital Affiliated to National Research Center for Rehabilitation Technical Aids; Shenzhen Nanshan District Shekou People's Hospital
First posted
Jun 27, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 45 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot study aims to assess the effectiveness and safety of rTMS in the treatment of movement disorders in patients with ICH.

Conditions

  • Intracerebral Hemorrhage

Interventions

  • rTMS with Magstim Rapid 2 magnetic stimulation deviceDevice

    The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.

  • sham control with Magstim Rapid 2 magnetic stimulation deviceDevice

    In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Fugl-Meyer Assessment (FMA)Time frame: Month 6

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Rehabilitation Hospital Affiliated to National Research Center for Rehabilitation Technical Aids

    Beijing, China · Recruiting

  • Shenzhen Qianhai Shekou Free Trade Zone Hospital

    Shenzhen, China · Recruiting

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.